Key Points
- William Mr. Burke, an AxoGen director, sold 11,431 shares on Nov. 5 at an average price of $24.05 for $274,915.55, leaving him with 100 shares — a 99.13% reduction in his position.
- AxoGen recently beat quarterly estimates with $0.12 EPS (vs. $0.09 expected) and $60.08M revenue (vs. $56.90M), and analysts have become more bullish overall, raising targets (average target ~$28.86) with eight Buys and one Sell rating.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director William Mr. Burke sold 5,347 shares of the company's stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.01, for a total transaction of $128,381.47. Following the sale, the director owned 100 shares in the company, valued at $2,401. This represents a 98.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
AxoGen Trading Down 1.8%
AXGN opened at $23.57 on Friday. The stock has a 50-day moving average of $17.89 and a 200 day moving average of $14.50. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $24.25. The firm has a market cap of $1.09 billion, a P/E ratio of -471.40 and a beta of 1.09.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.03. The business had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. AxoGen had a negative return on equity of 1.96% and a negative net margin of 0.98%. AxoGen has set its FY 2025 guidance at EPS. As a group, research analysts forecast that AxoGen, Inc. will post -0.29 EPS for the current year.
Analyst Ratings Changes
AXGN has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of AxoGen in a research report on Wednesday, October 8th. HC Wainwright raised their target price on shares of AxoGen from $25.00 to $26.00 and gave the stock a "buy" rating in a report on Thursday, October 30th. Citizens Jmp upped their price target on shares of AxoGen from $26.00 to $34.00 and gave the company a "market outperform" rating in a report on Thursday, October 30th. Wall Street Zen raised shares of AxoGen from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Raymond James Financial boosted their target price on AxoGen from $20.00 to $27.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $28.86.
View Our Latest Analysis on AxoGen
Hedge Funds Weigh In On AxoGen
A number of hedge funds have recently added to or reduced their stakes in AXGN. Balyasny Asset Management L.P. raised its stake in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider's stock valued at $20,953,000 after acquiring an additional 1,250,968 shares in the last quarter. Bessemer Group Inc. bought a new stake in AxoGen during the 3rd quarter valued at $14,468,000. Wasatch Advisors LP lifted its holdings in shares of AxoGen by 85.1% in the 2nd quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock worth $15,557,000 after buying an additional 659,149 shares during the period. Brown Capital Management LLC bought a new position in shares of AxoGen during the 3rd quarter worth $11,500,000. Finally, Armistice Capital LLC grew its position in shares of AxoGen by 106.5% during the 2nd quarter. Armistice Capital LLC now owns 1,111,319 shares of the medical equipment provider's stock worth $12,058,000 after buying an additional 573,041 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors.
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
